Izumu Saito

Izumu Saito

Auto-generated profile, based on publicly available information

Izumu Saito

Laboratory of Virology, Institute of Microbial Chemistry (BIKAKEN), Microbial Chemistry Foundation, Tokyo, Japan

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 1990 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
Izumu SaitoIzumu Saito
Izumu Saito
TMT Miyamura
T Miyamura
AOA Ohbayashi
A Ohbayashi
HHH Harada
H Harada
TKT Katayama
T Katayama
YOYasuyuki Ohta
Yasuyuki Ohta
A possible causative role for the recently discovered hepatitis C virus (HCV) in the development of hepatocellular carcinoma (HCC) was investigated by assay of sera from HCC patients in Japan for antibodies to a recombinant HCV antigen and to hepatitis B virus (HBV) antigens. Among the 253 HCC patients examined, 156 (61.7%) had no serum markers of either a previous or a current HBV infection (group I), 46 (18.2%) were negative for HBV surface antigen but positive for anti-HBV surface and/or anti-HBV core antibody, indicating the occurrence of a previous, transient HBV infection (group II), and 51 (20.2%) were chronically infected HBV carriers as evidenced by positivity for HBV surface antigen (group III). The prevalence of HCV antibody in group I (68.6%) and II (58.7%) patients was significantly higher than for group III (3.9%) or in 148 additional patients with other (non-HCC) cancers (10.1%) (P less than 0.01). Thus, there appears to be a strong association between HCV infection and the development of HCC, particularly in patients for which HBV infection cannot be implicated as a causative factor. The data also suggest an additional mode of transmission for HCV other than blood transfusion, since a history of blood transfusion was shown in only about 30% of the HCV antibody-positive HCC patients in groups I and II. A high prevalence of HCV antibody was also shown among patients with HCC whose disease was originally thought to be due to very high ethanol consumption.

1 January 1997 in Human Gene Therapy
Verified
Journal Article
Closed access
YHYuji Heike
Yuji Heike
MTMinako Takahashi
Minako Takahashi
YKYumi Kanegae
Yumi Kanegae
YSYumi Sato
Yumi Sato
Izumu SaitoIzumu Saito
Izumu Saito
NSNagahiro Saijo
Nagahiro Saijo
We evaluated the efficiency of gene transduction and of gene expression by adenoviral vectors in human lung adenocarcinoma cells. Freshly isolated cancer cells were collected from pleural effusions in adenocarcinoma patients by centrifugation with a Percoll gradient. Adenoviral vectors resulted in effective gene transduction into human lung cancer cell lines and into freshly isolated lung adenocarcinoma cells. In an experiment using the β-galactosidase (LacZ) gene, the Adex1CA vector with a regulatory sequence of chicken β-actin as promoter and an enhancer derived from cytomegalovirus produced a higher transduction ratio and greater expression levels than adenoviral vectors with other promoter systems. Transduction with Adex1CA vectors containing the human interleukin-2 (IL-2) gene (Adex1CAhIL-2) resulted in enhanced secretion of IL-2 from gene-modified lung cancer cells. Treatment with normal human serum inhibited gene transduction by Adex1CAhIL-2 but did not inhibit gene expression after transduction by Adex1CAhIL-2. The secretion of IL-2 from the gene-modified cells, which were irradiated at 100 Gy before transduction, continued for 8 days. In a mouse model, the intrapleural injection of IL-2 gene-modified 3LL cells transduced by Adex1CAhIL-2 could cure the pre-existing lung tumors with malignant pleural effusions to induce tumor-specific immunity. But these therapies did not show any therapeutic benefit on the pre-existing tumor in subcutaneous region. These data suggest a potentially useful but limited clinical role of Adex1CAhIL-2 in gene therapy for lung cancer patients. Heike et al. showed that the transduction could efficiently be done by the recombinant adenovirus containing the human interleukin-2 (IL-2) gene (Adex1CAhIL-2) and high IL-2 expression was observed in freshly isolated human lung adenocarcinoma cells. The secretion of IL-2 from the gene-modified cells, which were irradiated at 100 Gy before transduction, continued for 8 days. Treatment with normal human serum inhibited gene transduction by Adex1CAhlL-2. On the other hand, normal human serum had no effect on the expression of the transduced gene. Treatment with the human serum after gene transduction is reasonable strategy for gene therapy using ex vivo gene transduction by recombinant adenoviruses for inhibiting undesired gene transduction by free vectors in tumor vaccine suspension. In a mouse model, intrapleural injection of IL-2 gene-modified 3LL cells transduced by Adex1CAhIL-2 could cure pre-existing lung tumors with malignant pleural effusions to induce tumor-specific immunity but did not cure the pre-existing subcutaneous tumors nor extend the survival of the mice. Subcutaneous injection of IL-2 gene-modified 3LL cells did not cure the pre-existing lung 3LL tumors nor subcutaneous tumors and could not extend the survival of the mice, even though this treatment could induce tumor specific immunity to protect following 3LL challenge.

10 December 1998 in Human Gene Therapy
Verified
Journal Article
Closed access
NSNobusada Shinoura
Nobusada Shinoura
MOMakoto Ohashi
Makoto Ohashi
YYYoko Yoshida
Yoko Yoshida
AAAkio Asai
Akio Asai
TKTakaaki Kirino
Takaaki Kirino
HHHirofumi Hamada
Hirofumi Hamada
Generation of a recombinant adenovirus (Adv) that induces the constitutive expression of an apoptotic gene has been extremely difficult owing to severe apoptotic damage to the host cell. In this study, 293 cells were transduced with the caspase-inhibiting CrmA gene (293-CrmA cells), and used as host cells to generate Adv carrying apoptosis-inducing genes (proapoptotic genes). The 293-CrmA cells proved to be highly efficient for the construction of recombinant Adv carrying genes encoding Fas and Fas ligand. Moreover, the 293-CrmA line produced an ample quantity of these recombinant viruses. Because the conventional 293 plaque formation assay did not reflect the actual number of cells infected with the Adv carrying the proapoptotic gene, a determination of the Adv DNA copy number introduced into target cells was necessary to evaluate the quantity of infective virus. The techniques described here should be widely applicable for the construction of a recombinant Adv, in ample quantity, and for the estimation of the quantity of recombinant Adv produced. Recombinant adenoviruses (Advs) carrying proapoptotic genes, such as those encoding Fas and Fas ligand, will be useful tools for basic biological studies of immunity and oncogenesis, as well as in applications for cancer gene therapy. However, the damage to the host cells incurred by proapoptotic genes causes difficulties in construction and propagation of these Advs. In this study, we have developed an efficient method for the construction and ample propagation of Advs by using sublines of 293 cells transfected with the caspase-inhibiting gene. Because the titration of Advs carrying proapoptotic genes by plaque formation assay greatly underestimated the quantity of Advs, the introduced Adv DNA copy number should be an important parameter in the estimation of viral titer.

1 October 2006 in Microbiology and Immunology
Verified
Journal Article
Open access
PDF file
SKSaki Kondo
Saki Kondo
YTYuzuka Takahashi
Yuzuka Takahashi
SSSeiji Shiozawa
Seiji Shiozawa
HIHirotake Ichise
Hirotake Ichise
NYNobuaki Yoshida
Nobuaki Yoshida
Izumu SaitoIzumu Saito
Izumu Saito
Site‐specific recombinase is widely applied for the regulation of gene expression because its regulatory action is strict and efficient. However, each system can mediate regulation of only one gene at a time. Here, we demonstrate efficient “sequential” gene regulation using Cre‐ and FLP‐expressing recombinant adenovirus (rAd) in two different monitor cell lines, for regulation of one gene (OFF‐ON‐OFF) and for two genes (ON‐OFF and OFF‐ON, independently). Generally, serial use of Cre‐ and FLP‐expressing rAd tends to cause significant cytotoxicity, but we here described optimum dose of the rAds for serial regulation. We also established an efficient method of rAd infection to mouse ES cell lines after removing feeder cells, showing that this system is useful for removal of FRT‐flanked drug‐resistance gene cassette from recombinant ES cells prior to introduction of ES cells into blastocytes for chimeric mice production. Because our sequential gene‐regulation system offers efficient purpose‐gene regulation and strict OFF‐regulation, it is potentially valuable for elucidating not only novel gene functions using cDNA microarray analysis but also for “gene switching” in development and regeneration research.

26 July 2019 in The Journal of Gene Medicine
Verified
Journal Article
Open access
PDF file
TNTomoko Nakanishi
Tomoko Nakanishi
AMAya Maekawa
Aya Maekawa
HTHirotaka Tabata
Hirotaka Tabata
TYTakashi Yoshioka
Takashi Yoshioka
ZPZheng Pei
Zheng Pei
Izumu SaitoIzumu Saito
Izumu Saito
Background: Genome editing using the CRISPR/Cas9 system is now well documented in basic studies and is expected to be applied to gene therapy. Simultaneous expression of multiplex guide RNA (gRNA) and Cas9/Cas9 derivative is attractive for the efficient knockout of genes and a safe double‐nicking strategy. However, such use is limited because highly multiplex gRNA‐expressing units are difficult to maintain stably in plasmids as a result of deletion via homologous recombination.Methods: Lambda in vitro packaging was used instead of transformation for the construction and preparation of large, cos‐containing plasmid (cosmid). Polymerase chain reaction fragments containing multiplex gRNA units were obtained using the Four‐guide Tandem method. Transfection was performed by lipofection.Results: We constructed novel cosmids consisting of linearized plasmid‐DNA fragments containing up to 16 copies of multiplex gRNA‐expressing units as trimer or tetramer (polygonal cosmids). These cosmids behaved as if they were monomer plasmids, and multiplex units could stably be maintained and amplified with a lack of deletion. Surprisingly, the deleted cosmid was removed out simply by amplifying the cosmid stock using lambda packaging. The DNA fragments containing multiplex gRNA‐units and Cas9 were transfected to 293 cells and were found to disrupt the X gene of hepatitis B virus by deleting a large region between the predicted sites.Conclusions: We present a simple method for overcoming the problem of constructing plasmids stably containing multiplex gRNA‐expressing units. The method may enable the production of very large amounts of DNA fragments expressing intact, highly‐multiplex gRNAs and Cas9/Cas9 derivatives for safe and efficient genome‐editing therapy using non‐viral vectors.